CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L. Gillison, Robert L. Ferris, Jérôme Fayette et al.|The Oncologist|2018Cited by 96
Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancerDan Liu, Li Li|Oncology Letters|2017Cited by 15